CDK12BAL cells showed a vulnerability to targeting of CDK13 by sgRNA or CDK12/13 inhibitors and in vivo treatment of prostate cancer xenograft lines showed that tumors with CDK12BAL responded to the CDK12/13 inhibitor SR4835, while CDK12-intact lines did not. This evidence concerns the gene CDK13 and prostate cancer.